IMMIX BIOPHARMA INC (IMMX) Fundamental Analysis & Valuation

NASDAQ:IMMX • US45258H1068

Current stock price

9.3 USD
+0.37 (+4.14%)
At close:
9.35 USD
+0.05 (+0.54%)
After Hours:

This IMMX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. IMMX Profitability Analysis

1.1 Basic Checks

  • IMMX had negative earnings in the past year.
  • IMMX had a negative operating cash flow in the past year.
  • IMMX had negative earnings in each of the past 5 years.
  • IMMX had a negative operating cash flow in each of the past 5 years.
IMMX Yearly Net Income VS EBIT VS OCF VS FCFIMMX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M -25M

1.2 Ratios

  • The Return On Assets of IMMX (-28.08%) is better than 67.38% of its industry peers.
  • IMMX has a Return On Equity of -31.39%. This is in the better half of the industry: IMMX outperforms 74.56% of its industry peers.
Industry RankSector Rank
ROA -28.08%
ROE -31.39%
ROIC N/A
ROA(3y)-66.56%
ROA(5y)-77.78%
ROE(3y)-96.17%
ROE(5y)-97.32%
ROIC(3y)N/A
ROIC(5y)N/A
IMMX Yearly ROA, ROE, ROICIMMX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150 -200

1.3 Margins

  • IMMX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMMX Yearly Profit, Operating, Gross MarginsIMMX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. IMMX Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, IMMX has more shares outstanding
  • The number of shares outstanding for IMMX has been increased compared to 5 years ago.
  • IMMX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMMX Yearly Shares OutstandingIMMX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
IMMX Yearly Total Debt VS Total AssetsIMMX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • IMMX has an Altman-Z score of 24.42. This indicates that IMMX is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 24.42, IMMX belongs to the top of the industry, outperforming 90.10% of the companies in the same industry.
  • IMMX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 24.42
ROIC/WACCN/A
WACCN/A
IMMX Yearly LT Debt VS Equity VS FCFIMMX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 10.01 indicates that IMMX has no problem at all paying its short term obligations.
  • The Current ratio of IMMX (10.01) is better than 79.22% of its industry peers.
  • IMMX has a Quick Ratio of 10.01. This indicates that IMMX is financially healthy and has no problem in meeting its short term obligations.
  • IMMX has a Quick ratio of 10.01. This is in the better half of the industry: IMMX outperforms 79.42% of its industry peers.
Industry RankSector Rank
Current Ratio 10.01
Quick Ratio 10.01
IMMX Yearly Current Assets VS Current LiabilitesIMMX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. IMMX Growth Analysis

3.1 Past

  • IMMX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.05%.
EPS 1Y (TTM)-12.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 32.51% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y11.73%
EPS Next 2Y7.94%
EPS Next 3Y22.52%
EPS Next 5Y32.51%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMMX Yearly Revenue VS EstimatesIMMX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
IMMX Yearly EPS VS EstimatesIMMX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

1

4. IMMX Valuation Analysis

4.1 Price/Earnings Ratio

  • IMMX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMMX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMMX Price Earnings VS Forward Price EarningsIMMX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMMX Per share dataIMMX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as IMMX's earnings are expected to grow with 22.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.94%
EPS Next 3Y22.52%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IMMX Dividend Analysis

5.1 Amount

  • No dividends for IMMX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IMMX Fundamentals: All Metrics, Ratios and Statistics

IMMIX BIOPHARMA INC

NASDAQ:IMMX (5/1/2026, 8:00:02 PM)

After market: 9.35 +0.05 (+0.54%)

9.3

+0.37 (+4.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)03-25
Earnings (Next)05-06
Inst Owners47.71%
Inst Owner Change-0.01%
Ins Owners15.91%
Ins Owner Change0.03%
Market Cap492.99M
Revenue(TTM)N/A
Net Income(TTM)-29.44M
Analysts82
Price Target18.61 (100.11%)
Short Float %7.22%
Short Ratio3.93
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-49.9%
Min EPS beat(2)-75.97%
Max EPS beat(2)-23.84%
EPS beat(4)1
Avg EPS beat(4)-24.64%
Min EPS beat(4)-75.97%
Max EPS beat(4)36.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)40.38%
PT rev (3m)52.08%
EPS NQ rev (1m)-31.39%
EPS NQ rev (3m)-48.75%
EPS NY rev (1m)-56.12%
EPS NY rev (3m)-63.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.26
P/tB 5.26
EV/EBITDA N/A
EPS(TTM)-0.89
EYN/A
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS0
BVpS1.77
TBVpS1.77
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -28.08%
ROE -31.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.56%
ROA(5y)-77.78%
ROE(3y)-96.17%
ROE(5y)-97.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 298.17%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.01
Quick Ratio 10.01
Altman-Z 24.42
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1608.36%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
EPS Next Y11.73%
EPS Next 2Y7.94%
EPS Next 3Y22.52%
EPS Next 5Y32.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-50.92%
EBIT Next 3Y4.92%
EBIT Next 5YN/A
FCF growth 1Y-56.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.96%
OCF growth 3YN/A
OCF growth 5YN/A

IMMIX BIOPHARMA INC / IMMX Fundamental Analysis FAQ

What is the fundamental rating for IMMX stock?

ChartMill assigns a fundamental rating of 3 / 10 to IMMX.


What is the valuation status for IMMX stock?

ChartMill assigns a valuation rating of 1 / 10 to IMMIX BIOPHARMA INC (IMMX). This can be considered as Overvalued.


Can you provide the profitability details for IMMIX BIOPHARMA INC?

IMMIX BIOPHARMA INC (IMMX) has a profitability rating of 1 / 10.


Can you provide the financial health for IMMX stock?

The financial health rating of IMMIX BIOPHARMA INC (IMMX) is 8 / 10.